In this episode, the team explore emerging evidence across intrahepatic cholangiocarcinoma (iCCA), genomic therapy matching and chrono-oncology. As always, the discussion goes beyond headline results to consider the strength of evidence, clinical applicability and what these data may mean in practice.
Across topics, a consistent theme emerges: how do we interpret early signals, and when are they robust enough to influence patient care?
What’s covered
• The NeoGOLP trial in high-risk resectable iCCA, demonstrating improved event-free survival, with overall survival data still maturing
• Findings from the MoST programme, including the use of next-generation sequencing and molecular tumour boards, and observed survival associations when therapies are matched to biomarkers with strong supporting evidence
• The principles and practicalities of genomic therapy matching in personalised oncology care
• Chrono-oncology and the biological rationale for aligning treatment delivery with circadian rhythms
• The CHOPIN phase II trial in uveal melanoma, combining hepatic perfusion melphalan with ipilimumab and nivolumab, including signals for overall survival and considerations for real-world implementation
• Recent updates to ASCO living guidelines across lung, gastro-oesophageal and thyroid cancers
You can send us voice notes, connect with us on social media, and physicians can also claim CME points for listening.
From four time zones, we unpack new oncology research where endpoints, toxicity and generalisability matter as much as statistical significance.
